Moderna (MRNA) is back in focus after completing a clinical study of multiple mRNA vaccines targeting several respiratory ...
FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...
On Friday, the European Commission approved Moderna, Inc.’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower ...
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...
Add Yahoo as a preferred source to see more of our stories on Google. National Institutes of Health (NIH) Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ ...
From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...
CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
Moderna was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the ...
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results